# Pemvidutide

A weekly injection aimed at the liver first and weight second. It is also being tested in alcohol use disorder.

Also called: ALT-801
Source page: https://peplogue.com/peptides/pemvidutide/
Reviewed: 2026-10-12. Not medical advice.

## How it works

- Where it acts: GLP-1 and glucagon receptors, in equal balance.
- What it changes: Aimed at liver fat first: glucagon drives fat burning in the liver while GLP-1 lowers appetite.
- What people notice: In trials, less liver fat and inflammation, with weight loss as a second effect. Stomach side effects occur.

## What the evidence shows

- **Fatty liver disease (MASH)**: Supported. In a phase 2b trial MASH cleared in roughly half to six in ten people at 24 weeks, against about one in five on placebo. Scarring did not clearly improve in that time.
- **Alcohol use disorder**: Early. The company reported a positive result from a 100-person phase 2 trial in July 2026. The trial is small and unpublished.

## Side effects and risks

- common: Nausea and other stomach side effects.
- unknown: Longer-term safety is not known; the phase 3 trial reports in 2029.

Who should avoid it: Anyone outside a clinical trial.

## How it has been given in trials

Weekly injection under the skin. There is no approved dose.

## Legal status

- United States: undefined
- European Union: undefined
- Spain: undefined. Investigational. No authorised product in Spain (not in CIMA). The only lawful route is a clinical trial; Spanish trial sites not verified.
- Germany: undefined. Not authorised in Germany. Only available in clinical trials; sale outside trials is unlawful under the AMG (§ 21, § 96). German trial sites not checked.
- France: undefined. Investigational drug, not authorised in France. Only lawful route is a trial; ANSM says peptides bought outside the official circuit are illegal.
- Italy: undefined. Investigational. Not authorised in the EU or Italy; only reachable through a clinical trial. Italian trial sites not checked.
- Netherlands: undefined. Experimental. No marketing authorisation in the Netherlands or EU; only in clinical trials. Offering it as a medicine without authorisation is illegal.
- United Kingdom: undefined
- Canada: undefined
- Australia: undefined

## Questions people ask

**What is pemvidutide used for?**

It is aimed at fatty liver disease (MASH) first and weight second. It is also being tested in alcohol use disorder.

**Does pemvidutide work for fatty liver disease?**

In a phase 2b trial, MASH cleared in roughly half to six in ten people at 24 weeks, against about one in five on placebo. Scarring did not clearly improve in that time.

**Does pemvidutide help with alcohol use disorder?**

The company reported a positive result from a 100-person phase 2 trial in July 2026. The trial is small and unpublished.

**Is pemvidutide approved?**

No. A phase 3 liver trial has started and reports in 2029, and the drug has FDA Breakthrough designation.

## Sources

- Altimmune: second-quarter 2026 results and update: https://finviz.com/news/381074/altimmune-announces-second-quarter-2026-financial-results-and-business-update